Johnsen et al. investigated the therapeutic efficacy of rapamycin on neuroblastoma development in vivo and showed that tumor volume was significantly reduced and caspase 3 activation was increased in the rapamycin group compared to the control group [21]. This evidence concerns the gene CASP3 and neuroblastoma.